RA CAPITAL MANAGEMENT, L.P.
10% Owner; Director; Director, 10% Owner · 21 filings · Latest: May 8, 2026
Acrivon Therapeutics, Inc.
Acumen Pharmaceuticals, Inc.
Adicet Bio, Inc.
Bicara Therapeutics Inc.
Climb Bio, Inc.
Evommune, Inc.
Hemab Therapeutics Holdings, Inc.
Mineralys Therapeutics, Inc.
Prelude Therapeutics Inc
SpyGlass Pharma, Inc.
Vor Biopharma Inc.
Wave Life Sciences Ltd.
Werewolf Therapeutics, Inc.
| Ticker | Owner | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Filing |
|---|---|---|---|---|---|---|---|---|---|
VOR | RA CAPITAL MANAGEMENT, L.P. | Director, 10% Owner | Apr 8, 2026 | Sale | $16.48 | 484,104 | $8.0M | 4,071,637 | |
VOR | RA CAPITAL MANAGEMENT, L.P. | Director, 10% Owner | Apr 6, 2026 | Sale | $16.59 | 589,257 | $9.8M | 4,555,741 | |
VOR | RA CAPITAL MANAGEMENT, L.P. | Director, 10% Owner | Apr 2, 2026 | Sale | $18.23 | 260,000 | $4.7M | 5,144,998 | |
MLYS | RA CAPITAL MANAGEMENT, L.P. | Director | Mar 30, 2026 | Purchase | $24.16 | 58,300 | $1.4M | 5,825,521 | |
MLYS | RA CAPITAL MANAGEMENT, L.P. | Director | Mar 27, 2026 | Purchase | $23.67 | 310,700 | $7.4M | 5,767,221 | |
WVE | RA CAPITAL MANAGEMENT, L.P. | Director, 10% Owner | Mar 30, 2026 | Purchase | $6.50 | 971,091 | $6.3M | 26,975,505 | |
WVE | RA CAPITAL MANAGEMENT, L.P. | Director, 10% Owner | Mar 27, 2026 | Purchase | $6.43 | 2,495,623 | $16.0M | 26,004,414 | |
WVE | RA CAPITAL MANAGEMENT, L.P. | Director, 10% Owner | Mar 26, 2026 | Purchase | $6.08 | 5,305,782 | $32.3M | 23,508,791 | |
BCAX | RA CAPITAL MANAGEMENT, L.P. | Director, 10% Owner | Feb 26, 2026 | Purchase | $16.00 | 300,000 | $4.8M | 4,603,418 | |
SGP | RA CAPITAL MANAGEMENT, L.P. | Director, 10% Owner | Feb 9, 2026 | Purchase | $16.00 | 3,690,000 | $59.0M | 2,054,678 |
← Previous
Page 2 of 2